Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Classement en actions #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Prix de l'action
$0.00047446
Capitalisation boursière
$82.80
Changement (1 jour)
0.00%
Changement (1 an)
-98.16%
Pays
FR
Échange Neovacs S.A. (ALNEV)

Catégorie

Bénéfices pour Neovacs S.A. (ALNEV)
Bénéfices en Dec 2024 TTM : $-35.33M
Selon les derniers rapports financiers de Neovacs S.A., les bénéfices actuels de l'entreprise sont de $-35.33M. En 2023, l'entreprise a réalisé un bénéfice de $-10.63M, une diminution par rapport à celui de 2022 qui était de $-4.66M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Neovacs S.A. de 2007 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-35.33M 0.00%
2024 $-35.33M 232.17%
2023 $-10.63M 128.13%
2022 $-4.66M -67.15%
2021 $-14.19M 74.31%
2020 $-8.14M -22.00%
2019 $-10.44M -33.00%
2018 $-15.58M -31.17%
2017 $-22.63M 24.13%
2016 $-18.23M 131.65%
2015 $-7.87M -33.75%
2014 $-11.88M 7.75%
2013 $-11.03M 0.62%
2012 $-10.96M -12.83%
2011 $-12.57M -8.71%
2010 $-13.77M 14.01%
2009 $-12.08M 72.06%
2008 $-7.02M -9.80%
2007 $-7.78M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$20.51B -58,146.44%
DK
$4.64B -13,244.00%
US
$5.23B -14,907.10%
US
$2.14B -6,151.40%
BE
$1.45B -4,207.73%
NL